← The Wire
CYTKNasdaq
CYTOKINETICS INC
Pharmaceutical Preparations · CIK 1061983
CYTOKINETICS INC develops and commercializes drug products, with recent FDA approval for MYQORZO
$9.52B
Market cap
$87.26
Last close
+6.2%
1D
+10.2%
5D
3.6M
Volume
Price · last 39 sessions+32.1%
May 4L $66.05 · H $87.26Jun 29
189
Total filings
May 27, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteMay 27, 20268-KCompany UpdateMay 8, 2026424B5424B5May 7, 2026424B5424B5May 5, 20268-KCompany UpdateMay 5, 202610-Q10-QMay 5, 20268-KResults of OperationsMay 5, 2026DEF 14ADEF 14AApr 17, 202610-K10-KFeb 26, 20268-KResults of OperationsFeb 24, 20268-KCompany UpdateFeb 17, 20268-KCompany UpdateDec 19, 20258-KCompany UpdateDec 12, 20258-KExecutive ChangeNov 14, 202510-Q10-QNov 5, 20258-KResults of OperationsNov 5, 20258-KMaterial Agreement · New Debt / ObligationSep 22, 20258-KCompany UpdateSep 16, 20258-K/ACompany UpdateSep 8, 20258-KCompany UpdateSep 3, 20258-KCompany UpdateSep 2, 20258-KExecutive ChangeAug 20, 202510-Q10-QAug 7, 20258-KResults of OperationsAug 7, 20258-KShareholder VoteMay 16, 202510-Q10-QMay 6, 20258-KResults of OperationsMay 6, 20258-KCompany UpdateMay 1, 2025DEF 14ADEF 14AApr 10, 20258-KReg FD DisclosureMar 10, 202510-K10-KFeb 27, 20258-KResults of OperationsFeb 27, 20258-KExecutive ChangeFeb 11, 20258-KExecutive ChangeDec 16, 20248-KMaterial AgreementNov 19, 2024SC 13GSC 13GNov 14, 202410-Q10-QNov 7, 20248-KExecutive ChangeNov 7, 20248-KExecutive ChangeAug 15, 202410-Q10-QAug 9, 20248-KResults of OperationsAug 8, 20248-KCompany UpdateJun 7, 20248-KReg FD DisclosureJun 5, 20248-KCompany UpdateMay 28, 2024424B5424B5May 24, 2024424B5424B5May 22, 20248-KCompany UpdateMay 22, 20248-KMaterial Agreement · Acquisition / DispositionMay 22, 20248-KExecutive Change · Shareholder VoteMay 17, 20248-KCompany UpdateMay 13, 202410-Q10-QMay 10, 20248-KResults of OperationsMay 8, 20248-KCompany UpdateMay 8, 20248-KCompany UpdateMay 8, 20248-KExecutive ChangeApr 26, 2024DEF 14ADEF 14AApr 8, 20248-KCompany UpdateApr 5, 202410-K10-KFeb 28, 20248-KResults of OperationsFeb 27, 20248-KExecutive ChangeFeb 2, 20248-KCompany UpdateDec 27, 20238-KSecurity-Holder Rights · Bylaw AmendmentNov 17, 202310-Q10-QNov 3, 20238-KResults of OperationsNov 2, 20238-KReg FD DisclosureOct 19, 20238-KCompany UpdateOct 6, 20238-KExecutive ChangeOct 3, 202310-Q10-QAug 3, 20238-KResults of OperationsAug 3, 20238-KCompany UpdateMay 23, 20238-KCompany UpdateMay 11, 20238-KShareholder VoteMay 11, 202310-Q10-QMay 5, 20238-KResults of OperationsMay 4, 2023DEF 14ADEF 14AApr 7, 20238-KCompany UpdateMar 31, 20238-KCompany UpdateMar 6, 2023424B5424B5Mar 1, 202310-K10-KMar 1, 20238-KResults of OperationsMar 1, 2023
Insider Activity
In the 90 days to Mar 31, 2026: 5 sold $9.1M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 31, 2026 | Callos AndrewEVP, Chief Commercial Officer | Sell | 3,639 | $65.00 | $237K |
| Mar 18, 2026 | Callos AndrewEVP, Chief Commercial Officer | Sell | 1,930 | $62.07 | $120K |
| Mar 17, 2026 | Blum Robert IPresident & CEO | Sell | 23,928 | $62.15 | $1.5M |
| Mar 17, 2026 | Blum Robert IPresident & CEO | Sell | 12,673 | $62.15 | $788K |
| Mar 17, 2026 | Malik Fady IbrahamEVP Research & Development | Sell | 7,636 | $62.15 | $475K |
| Mar 17, 2026 | Callos AndrewEVP, Chief Commercial Officer | Sell | 5,626 | $62.15 | $350K |
| Mar 17, 2026 | Lee SungEVP, Chief Financial Officer | Sell | 4,935 | $62.15 | $307K |
| Mar 17, 2026 | Malik Fady IbrahamEVP Research & Development | Sell | 4,397 | $62.15 | $273K |
| Mar 17, 2026 | Callos AndrewEVP, Chief Commercial Officer | Sell | 2,916 | $62.15 | $181K |
| Mar 16, 2026 | Callos AndrewEVP, Chief Commercial Officer | Sell | 1,709 | $61.03 | $104K |
| Mar 9, 2026 | Blum Robert IPresident & CEO | Sell | 7,931 | $60.72 | $482K |
| Mar 9, 2026 | Malik Fady IbrahamEVP Research & Development | Sell | 2,907 | $60.72 | $177K |
| Mar 9, 2026 | Callos AndrewEVP, Chief Commercial Officer | Sell | 2,582 | $60.72 | $157K |
| Mar 5, 2026 | Callos AndrewEVP, Chief Commercial Officer | Sell | 15,000 | $61.87 | $928K |
| Mar 5, 2026 | Callos AndrewEVP, Chief Commercial Officer | Sell | 11,000 | $61.88 | $681K |
| Mar 2, 2026 | Parshall B LynneDirector | Sell | 5,000 | $61.21 | $306K |
| Mar 2, 2026 | Callos AndrewEVP, Chief Commercial Officer | Sell | 886 | $61.62 | $55K |
| Feb 5, 2026 | Callos AndrewEVP, Chief Commercial Officer | Sell | 15,000 | $61.93 | $929K |
| Feb 2, 2026 | Callos AndrewEVP, Chief Commercial Officer | Sell | 886 | $62.10 | $55K |
| Jan 5, 2026 | Callos AndrewEVP, Chief Commercial Officer | Sell | 15,000 | $60.28 | $904K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance